The Adcetris FDA Letter: What It Means for MLR Review and Promotional Compliance

In April 2026, the FDA’s Office of Prescription Drug Promotion (OPDP) issued an Untitled Letter related to promotional materials for Adcetris, highlighting concerns about how the therapy was presented in digital advertising. While Untitled Letters are less severe than Warning Letters, they indicate that the FDA believes promotional content may be false or misleading under the Federal Food, Drug, and Cosmetic Act.

For pharmaceutical companies, situations like this reinforce a reality that Regulatory, Medical, and Legal (MLR) teams face every day: ensuring promotional materials meet strict FDA requirements across rapidly expanding marketing channels.

With the growth of digital campaigns, social media, and omnichannel marketing strategies, MLR review processes are under increasing pressure to move quickly while maintaining regulatory accuracy.

Why This Matters for MLR Teams

MLR review exists to ensure that promotional materials are accurate, balanced, and compliant with FDA promotional regulations before they reach healthcare professionals or patients.

However, even well-established MLR processes can struggle with several challenges:

• Complex promotional claims embedded within long-form or multimedia content
• Evolving FDA promotional guidance that teams must continuously interpret
• Large volumes of promotional assets moving through the MLR workflow
• Institutional knowledge gaps when prior FDA letters or enforcement actions are not easily accessible during review

When MLR teams must manually cross-check claims, labeling, references, and risk disclosures, the process can become both time-consuming and prone to oversight.

This is particularly true in large organizations managing multiple brands, agencies, and promotional campaigns simultaneously.

The Increasing Complexity of Promotional Review

The Adcetris case reflects a broader industry trend: FDA scrutiny of pharmaceutical advertising is increasing, particularly in digital channels where messaging can be shorter, more visual, and easier to misinterpret.

For MLR teams, this creates additional pressure to ensure that promotional content:

• Accurately reflects approved indications and patient populations
• Includes appropriate risk disclosures
• Avoids overgeneralization of clinical results
• Maintains fair balance between benefits and risks

These requirements must be validated across multiple content formats—from websites and banner ads to social media and patient education materials.

As promotional channels expand, traditional MLR workflows often struggle to keep pace.

Where Traditional MLR Systems Fall Short

Many organizations still rely on manual promotional review processes, static claims libraries, or shared regulatory documentation when reviewing marketing content.

While these approaches provide structure, they can create several limitations:

• Claims libraries often become outdated or difficult to maintain
• FDA guidance and enforcement trends may not be easily accessible during review
• Prior OPDP letters and regulatory feedback often live in internal archives rather than in the review workflow itself
• Review cycles become longer and more resource-intensive

As a result, MLR teams frequently spend valuable time tracking claims, verifying references, and interpreting regulatory guidance manually.

How ERMA Supports Modern MLR Workflows

This is exactly the challenge ERMA was designed to solve.

ERMA is an AI-powered MLR platform built specifically for pharmaceutical and biotech teams, helping regulatory, medical, legal, and commercial stakeholders streamline promotional review while maintaining confidence in compliance.

AI-Powered Claims Identification

ERMA automatically scans promotional materials to identify marketing claims embedded within text, visuals, and long-form content.

Instead of relying on static claims libraries, the platform dynamically analyzes promotional messaging and highlights areas that require supporting evidence.

This helps MLR reviewers focus on substantiation and regulatory alignment, rather than manually searching for claims throughout the document.

Automated Reference Assignment

Once claims are identified, ERMA helps assign supporting references and clinical citations, enabling faster verification of promotional messaging.

This allows medical reviewers and regulatory teams to quickly confirm whether statements are accurately supported by clinical data or labeling information.

An FDA Knowledge Base for Promotional Compliance

One of ERMA’s most powerful capabilities is its FDA regulatory knowledge base, which continuously validates promotional content against current FDA promotional guidance.

This knowledge base allows the platform to flag potential compliance risks related to:

• Incomplete indication statements
• Missing or insufficient risk disclosures
• Overstated efficacy claims
• Messaging that may conflict with approved labeling

By integrating regulatory intelligence directly into the MLR workflow, ERMA helps teams identify potential issues earlier in the review process.

Learning From FDA Letters and Enforcement Actions

Another key feature of ERMA is the ability to store and reference FDA letters, OPDP enforcement actions, and prior regulatory feedback directly within the platform.

Instead of existing as isolated documents within compliance archives, these letters become part of the review system itself.

This enables organizations to:

• Preserve institutional knowledge across MLR teams
• Apply lessons learned from past FDA enforcement actions
• Proactively identify promotional messaging that may create similar regulatory concerns

In essence, ERMA allows companies to turn past regulatory events into actionable intelligence for future promotional review.

The Future of MLR Review

As pharmaceutical marketing becomes more digital and data-driven, the role of MLR teams will continue to evolve.

Regulatory reviewers must now evaluate a greater volume of promotional materials across more channels than ever before, while still ensuring that every piece of content aligns with FDA expectations.

Platforms like ERMA represent a new generation of AI-enabled MLR technology that helps life sciences organizations modernize promotional review by combining:

• Automated claim detection
• Reference management
• Regulatory knowledge databases
• Flexible MLR workflows
• Audit-ready documentation

By embedding regulatory intelligence directly into the promotional review process, companies can reduce review bottlenecks while strengthening promotional compliance.

Turning Regulatory Lessons Into Operational Intelligence

Events like the Adcetris letter serve as an important reminder that promotional compliance is not static—it evolves alongside marketing innovation.

For MLR teams, the challenge is not only reviewing content but also capturing institutional regulatory knowledge and applying it to future campaigns.

The organizations that succeed in this environment will be those that integrate compliance intelligence directly into their MLR workflows, allowing teams to review materials faster while maintaining confidence in regulatory accuracy.

With AI-powered platforms like ERMA, pharmaceutical companies can transform promotional review from a manual checkpoint into a proactive, knowledge-driven process.